The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.

ABSTRACT:

Background

Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) represent a deep revolution of the therapeutic approach to heart failure (HF), preventing its insurgence but also improving the management of the disease and slowing its natural progression. To date, few studies have explored the effectiveness of SGLT2i and, in particular, Dapagliflozin in a real-world population. Therefore, in this observational prospective study, we evaluated Dapagliflozin's effectiveness in a real-world HF population categorized in the different hemodynamic profiles.

Methods

From January 2022 to June 2023, we enrolled 240 patients with chronic HF and reduced ejection fraction (HFrEF) on optimal medical therapy, according to 2021 ESC guidelines, that added treatment with Dapagliflozin from the H

SUBMITTER: Loria F 

PROVIDER: S-EPMC11583416 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature